1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25 | Licensing Program Analyst Avelina Martinez contacted the facility via telephone to conduct a case management on 04/16/2021 due to COVID-19 and pre-cautionary measures. LPA identified herself and discussed the purpose of the call and the elements of the case management with Mary Keaton
The purpose of the case management visit is to follow up on a medication deficiency learned throughout a complaint investigation (27-AS-20200930112221). The following medication deficiency was discovered:
March 2020 Medication Administration Record (MAR) indicates Tea Tree oil was added to R1's routine medication. However, March, April, and May MAR sheets for Tea tree oil are blank. June’s 2020 MAR for Tea Tree oil is incomplete; June 1st, 2nd, 18th, and 19th entries are blank. The other June entries are initialed and circled. Based on the medication file review, the licensee did not ensure to maintain R1's MAR sheets and did not maintain oversight on the Tea Tree oil medication while in the facility.
As a result, the following deficiency was observed and cited from the California Code of Regulations, Title 22, and California Health and Safety Code. An exit interview was conducted with Mary Keaton via telephone, and a copy of this report was provided to Mary Keaton via email, and an electronic email read receipt confirms receiving these documents.
|